{"id":"NCT01606202","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury","officialTitle":"A Randomised, Double Blind, Placebo Controlled, Parallel Group Comparative Study of the Efficacy, Safety and Tolerability of Sublingual Cannabis Based Medicine Extracts and Placebo in Patients With Intractable Neuropathic Pain Associated With Spinal Cord Injury","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-07","primaryCompletion":"2005-01","completion":"2005-01","firstPosted":"2012-05-25","resultsPosted":"2012-09-28","lastUpdate":"2023-01-10"},"enrollment":116,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain"],"interventions":[{"type":"DRUG","name":"GW-1000-02","otherNames":["Sativex"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"GW-1000-02","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to investigate the effects of sublingual cannabis based medicine extracts on neuropathic pain associated with spinal cord injury.","primaryOutcome":{"measure":"Change From Baseline in Mean Central Neuropathic Pain 11-Point Numerical Rating Scale Scores at the End of Treatment (up to 51 Days).","timeFrame":"Up to 51 days","effectByArm":[{"arm":"GW-1000-02","deltaMin":-0.74,"sd":1.12},{"arm":"Placebo","deltaMin":-0.69,"sd":1.39}],"pValues":[{"comp":"OG000 vs OG001","p":"0.708"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":18},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["33465022"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":56},"commonTop":["Dizziness","Dysgeusia","Urinary Tract Infection Not Otherwise Specified","Nausea","Somnolence"]}}